Strategy (work plan)

OVER-MYR integrates a network of outstanding researchers from 6 EU countries with internationally recognized experience in clinics and human and animal models of MM, who will jointly reach their objectives through complementary and interactive workpackages (WPs):


WP1: will examine the molecular alterations in primary MM and niche cells at presentation and relapse using high throughput techniques.


WP2
: will implement in vitro and in vivo models to determine underlying molecular and cellular mechanisms of drug resistance, and compare with drug resistance pathways elucidated in patients (WP1). Key pathways and core genes will be investigated in depth in WP2.


WP3
: will determine how specific immune niche cells alter tumor functions in the presence of drugs.


WP4
: will screen chemical libraries for drugs to overcome pathways of resistance to current drugs, and develop innovative modulators for a proof of principal Phase I/II trial

 

tab over myr

Overmyr © 2012